Vanguard Group
IRD

Vanguard Group’s Opus Genetics IRD Stock Holding History

Vanguard Group’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$4.67M Buy
2,322,897
+980,872
+73% +$1.99M ﹤0.01% 3280
2025
Q3 		$2.21M Buy
1,342,025
+349,825
+35% +$435K ﹤0.01% 3549
2025
Q2 		$935K Hold
992,200
– – ﹤0.01% 3760
2025
Q1 		$974K Hold
992,200
– – ﹤0.01% 3717
2024
Q4 		$1.18M Hold
992,200
– – ﹤0.01% 3707
2024
Q3 		$1.3M Hold
992,200
– – ﹤0.01% 3694
2024
Q2 		$1.52M Hold
992,200
– – ﹤0.01% 3648
2024
Q1 		$1.99M Buy
992,200
+64,400
+7% +$163K ﹤0.01% 3597
2023
Q4 		$2.79M Buy
927,800
+68,995
+8% +$204K ﹤0.01% 3481
2023
Q3 		$2.88M Sell
858,805
-27,073
-3% -$109K ﹤0.01% 3469
2023
Q2 		$3.84M Buy
885,878
+39,176
+5% +$186K ﹤0.01% 3432
2023
Q1 		$3.18M Buy
846,702
+143,348
+20% +$515K ﹤0.01% 3507
2022
Q4 		$2.48M Buy
703,354
+266
+0% +$700 ﹤0.01% 3587
2022
Q3 		$1.41M Hold
703,088
– – ﹤0.01% 3881
2022
Q2 		$1.35M Hold
703,088
– – ﹤0.01% 3982
2022
Q1 		$2.28M Hold
703,088
– – ﹤0.01% 3904
2021
Q4 		$2.62M Sell
703,088
-277,649
-28% -$1.11M ﹤0.01% 3940
2021
Q3 		$5.05M Buy
980,737
+943,591
+2,540% +$4.35M ﹤0.01% 3657
2021
Q2 		$196K Buy
37,146
+23,426
+171% +$116K ﹤0.01% 4372
2021
Q1 		$79K Sell
13,720
-595
-4% -$5.53K ﹤0.01% 4324
2020
Q4 		$93K Sell
14,315
-4,641
-24% -$32.1K ﹤0.01% 4149
2020
Q3 		$158K Buy
18,956
+5,236
+38% +$50.9K ﹤0.01% 3977
2020
Q2 		$156K Sell
13,720
-176
-1% -$1.62K ﹤0.01% 3950
2020
Q1 		$99K Hold
13,896
– – ﹤0.01% 3947
2019
Q4 		$106K Hold
13,896
– – ﹤0.01% 4003
2019
Q3 		$113K Sell
13,896
-279
-2% -$3.88K ﹤0.01% 4024
2019
Q2 		$293K Sell
14,175
-20,096
-59% -$454K ﹤0.01% 3909
2019
Q1 		$839K Buy
34,271
+4,357
+15% +$145K ﹤0.01% 3674
2018
Q4 		$1.33M Buy
29,914
+6,793
+29% +$397K ﹤0.01% 3479
2018
Q3 		$1.98M Buy
23,121
+19
+0.1% +$1.47K ﹤0.01% 3535
2018
Q2 		$1.56M Buy
23,102
+18
+0.1% +$1.58K ﹤0.01% 3566
2018
Q1 		$1.67M Buy
23,084
+3,369
+17% +$306K ﹤0.01% 3521
2017
Q4 		$1.91M Buy
19,715
+2,932
+17% +$298K ﹤0.01% 3431
2017
Q3 		$1.95M Sell
16,783
-741
-4% -$79.9K ﹤0.01% 3407
2017
Q2 		$2.4M Buy
17,524
+6,645
+61% +$1.29M ﹤0.01% 3329
2017
Q1 		$2.66M Buy
10,879
+6,115
+128% +$793K ﹤0.01% 3290
2016
Q4 		$324K Sell
4,764
-5,501
-54% -$448K ﹤0.01% 3813
2016
Q3 		$1.03M Buy
10,265
+48
+0.5% +$5.8K ﹤0.01% 3566
2016
Q2 		$1.23M Buy
10,217
+104
+1% +$14.6K ﹤0.01% 3545
2016
Q1 		$1.6M Sell
10,113
-91
-0.9% -$15.1K ﹤0.01% 3451
2015
Q4 		$1.78M Buy
10,204
+79
+0.8% +$16.8K ﹤0.01% 3437
2015
Q3 		$2.53M Buy
10,125
+84
+0.8% +$22.8K ﹤0.01% 3270
2015
Q2 		$2.93M Buy
10,041
+355
+4% +$121K ﹤0.01% 3254
2015
Q1 		$3.39M Buy
9,686
+647
+7% +$235K ﹤0.01% 3185
2014
Q4 		$3.04M Buy
9,039
+485
+6% +$167K ﹤0.01% 3118
2014
Q3 		$3.33M Buy
8,554
+1,108
+15% +$399K ﹤0.01% 3048
2014
Q2 		$3.11M Buy
7,446
+41
+0.6% +$18.6K ﹤0.01% 3060
2014
Q1 		$3.84M Buy
7,405
+3,283
+80% +$1.78M ﹤0.01% 2956
2013
Q4 		$1.01M Hold
4,122
– – ﹤0.01% 3412
2013
Q3 		$890K Buy
4,122
+2,494
+153% +$582K ﹤0.01% 3403
2013
Q2 		$347K Buy
+1,628
New +$279K ﹤0.01% 3555

Other funds holding IRD

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $179M AUM 37.68% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group's IRD Position: Q4 2025 in Review

Vanguard Group increased its Opus Genetics (IRD) stake by 73% in Q4 2025, buying an estimated $1.99M and bringing the position to 2,322,897 shares worth $4.67M. The position accounts for ﹤0.01% of the portfolio, ranked #3280.

Vanguard Group first reported a position in IRD in Q2 2013 and has held it in 51 quarters since. The position peaked at $5.05M in Q3 2021. 59 funds tracked by Wall St. Rank hold IRD as of Q4 2025.

  • Vanguard Group held 2,322,897 shares of Opus Genetics worth $4.67M as of Q4 2025.
  • Vanguard Group bought 980,872 Opus Genetics shares in Q4 2025, an estimated $1.99M.
  • Opus Genetics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3280 holding.
  • Vanguard Group first reported a position in Opus Genetics in Q2 2013 and has held it in 51 quarters since.
  • Vanguard Group's Opus Genetics position peaked at $5.05M in Q3 2021.
  • 59 funds tracked by Wall St. Rank held Opus Genetics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.